A PHASE 2 OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY, EFFICACY, AND PHARMACOKINETICS OF AOC 1020 ADMINISTERED INTRAVENOUSLY TO ADULT PARTICIPANTS WITH FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD)

Registry ID

AOC 1020-CS2

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

AVIDITY BIOSCIENCES

Start date

2026-07-23

Last update

2024-08-15

Conditions

• FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY

Related clinical trials

• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAVENOUS AOC 1020 FOR THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD)
• A BICENTRIC, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED PILOT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SATRALIZUMAB IN FSHD1
• A PHASE 1/2A DOSE-ESCALATING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ARO-DUX4 IN ADULT PATIENTS AND ADOLESCENT PATIENTS WITH FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY TYPE 1
• A PHASE 1/2A DOSE-ESCALATING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ARO-DUX4 IN ADULT PATIENTS WITH FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY TYPE 1
• AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM EFFECTS OF ACE-083 IN PATIENTS WITH FSHD PREVIOUSLY ENROLLED IN STUDY A083-02 AND IN PATIENTS WITH CMT DISEASE TYPES 1 AND X PREVIOUSLY ENROLLED IN STUDY A083-03

View on source registry